Volume | 528,017 |
|
|||||
News | - | ||||||
Day High | 4.24 | Low High |
|||||
Day Low | 4.035 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Sutro Biopharma Inc | STRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.15 | 4.035 | 4.24 | 4.14 | 4.08 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
4,548 | 528,017 | US$ 4.14 | US$ 2,186,548 | - | 2.005 - 6.13 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:57:32 | formt | 1,028 | US$ 4.20 | USD |
Sutro Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
252.96M | 60.95M | - | 153.73M | -106.79M | -1.75 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sutro Biopharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STRO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.18 | 5.0895 | 3.99 | 4.51 | 1,634,185 | 0.02 | 0.48% |
1 Month | 3.41 | 5.0895 | 3.345 | 4.23 | 874,136 | 0.79 | 23.17% |
3 Months | 4.94 | 6.13 | 3.20 | 4.41 | 1,071,770 | -0.74 | -14.98% |
6 Months | 2.55 | 6.13 | 2.13 | 4.22 | 944,797 | 1.65 | 64.71% |
1 Year | 5.27 | 6.13 | 2.005 | 4.12 | 730,442 | -1.07 | -20.30% |
3 Years | 18.37 | 23.70 | 2.005 | 6.82 | 571,785 | -14.17 | -77.14% |
5 Years | 10.38 | 28.30 | 2.005 | 9.24 | 438,197 | -6.18 | -59.54% |
Sutro Biopharma Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. |